The report on the global diabetes devices and drugs market provides qualitative and quantitative analysis for the period from 2021-2030. The global diabetes devices and drugs market was valued at USD 159.1 billion in 2022 and is expected to reach USD 383.6 billion in 2030, with a CAGR of 10.18% during the forecast period 2023-2030. The study on diabetes devices and drugs market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.
The report on diabetes devices and drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global diabetes devices and drugs market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global diabetes devices and drugs market over the period of 2021-2030. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.
Report Findings
1) Drivers
- The increase in product approvals and new product launches are propelling the growth of market.
- The increasing patient suffering from diabetes is a significant driver of the market.
2) Restraints
- Stringent regulatory hurdles and compliance requirements can act as a barrier to market growth.
3) Opportunities
- The ongoing advancements in genetics, biomarkers, and data analytics present prominent opportunities for market growth.
Research Methodology
A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry
The primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.
The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segment Covered
The global diabetes devices and drugs market is segmented on the basis of type, and end user.
The Global Diabetes Devices and Drugs Market by Type
- Devices
- Drugs
The Global Diabetes Devices and Drugs Market by End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Home Care Centers
- Self-care
Company Profiles
The companies covered in the report include:
- Novo Nordisk A/S
- Ypsomed AG
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- Eli Lilly and Company
- Hoffmann-La Roche Ltd.
- Johnson & Johnson Inc.
- Medtronic
- BD
- Terumo Corporation
What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the diabetes devices and drugs market.
2. Complete coverage of all the segments in the diabetes devices and drugs market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global diabetes devices and drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Novo Nordisk A/S
- Ypsomed AG
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- Eli Lilly and Company
- Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Medtronic PLC
- Becton, Dickinson and Company
- Terumo Corporation
